Coya Therapeutics (COYA) Competitors $5.72 -0.14 (-2.30%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock COYA vs. AMLX, PRTA, PRTC, ABVX, TRML, PGEN, RGNX, MREO, ERAS, and KMDAShould you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include Amylyx Pharmaceuticals (AMLX), Prothena (PRTA), PureTech Health (PRTC), ABIVAX Société Anonyme (ABVX), Tourmaline Bio (TRML), Precigen (PGEN), REGENXBIO (RGNX), Mereo BioPharma Group (MREO), Erasca (ERAS), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. Coya Therapeutics vs. Amylyx Pharmaceuticals Prothena PureTech Health ABIVAX Société Anonyme Tourmaline Bio Precigen REGENXBIO Mereo BioPharma Group Erasca Kamada Coya Therapeutics (NASDAQ:COYA) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment. Do insiders & institutionals believe in COYA or AMLX? 39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 9.8% of Coya Therapeutics shares are held by insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is COYA or AMLX more profitable? Coya Therapeutics' return on equity of -31.63% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -31.63% -27.76% Amylyx Pharmaceuticals N/A -36.97%-29.61% Do analysts prefer COYA or AMLX? Coya Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 199.82%. Amylyx Pharmaceuticals has a consensus target price of $9.83, suggesting a potential upside of 81.09%. Given Coya Therapeutics' higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Amylyx Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13 Which has more volatility & risk, COYA or AMLX? Coya Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.6, indicating that its share price is 160% less volatile than the S&P 500. Does the MarketBeat Community believe in COYA or AMLX? Amylyx Pharmaceuticals received 13 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 96.30% of users gave Coya Therapeutics an outperform vote while only 69.64% of users gave Amylyx Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCoya TherapeuticsOutperform Votes2696.30% Underperform Votes13.70%Amylyx PharmaceuticalsOutperform Votes3969.64% Underperform Votes1730.36% Which has stronger valuation & earnings, COYA or AMLX? Amylyx Pharmaceuticals has lower revenue, but higher earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$3.69M25.73-$7.99M-$1.07-5.30Amylyx Pharmaceuticals-$1.27M-380.53$49.27M-$3.11-1.75 Does the media refer more to COYA or AMLX? In the previous week, Coya Therapeutics had 7 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 15 mentions for Coya Therapeutics and 8 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.89 beat Coya Therapeutics' score of 0.46 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Amylyx Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCoya Therapeutics and Amylyx Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COYA vs. The Competition Export to ExcelMetricCoya TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$94.83M$6.49B$5.36B$8.39BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-8.728.9426.5919.72Price / Sales25.73251.55391.61116.20Price / CashN/A65.8538.2534.62Price / Book2.306.466.794.51Net Income-$7.99M$143.98M$3.23B$248.18M7 Day Performance-0.35%3.16%4.03%1.14%1 Month Performance-0.70%7.60%12.22%15.07%1 Year Performance-31.69%-2.36%16.76%6.59% Coya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COYACoya Therapeutics2.1183 of 5 stars$5.67-3.2%$17.00+199.8%-34.1%$94.83M$3.69M-8.726Trending NewsAnalyst RevisionGap UpAMLXAmylyx Pharmaceuticals3.4977 of 5 stars$4.60-0.2%$9.67+110.1%+200.0%$409.79M$-1,272,000.00-1.20200PRTAProthena3.7916 of 5 stars$7.61+2.4%$51.71+579.6%-67.8%$409.62M$137.94M-3.31130High Trading VolumePRTCPureTech Health1.5357 of 5 stars$17.03+1.5%$45.00+164.3%-39.3%$408.92M$4.32M0.00100Gap UpABVXABIVAX Société Anonyme2.6067 of 5 stars$6.40-4.6%$34.00+431.3%-58.1%$405.88MN/A0.0061Positive NewsGap DownTRMLTourmaline Bio2.0714 of 5 stars$15.78+4.5%$49.33+212.6%+11.3%$405.31MN/A-5.6044News CoveragePGENPrecigen3.4625 of 5 stars$1.37+3.0%$7.00+410.9%+1.4%$404.38M$3.93M-2.49190News CoverageEarnings ReportAnalyst RevisionGap DownHigh Trading VolumeRGNXREGENXBIO4.3016 of 5 stars$7.97+6.0%$31.63+296.8%-37.0%$399.43M$83.33M-1.58370Analyst RevisionMREOMereo BioPharma Group1.944 of 5 stars$2.50+3.7%$7.71+208.6%-29.4%$397.50M$1M-41.6740Positive NewsGap UpERASErasca3.639 of 5 stars$1.39flat$4.83+247.7%-42.9%$393.77MN/A-1.67120Gap DownKMDAKamada3.9437 of 5 stars$6.82-0.9%$14.67+115.1%+26.8%$392.01M$160.95M24.36360Earnings ReportAnalyst RevisionGap Down Related Companies and Tools Related Companies Amylyx Pharmaceuticals Competitors Prothena Competitors PureTech Health Competitors ABIVAX Société Anonyme Competitors Tourmaline Bio Competitors Precigen Competitors REGENXBIO Competitors Mereo BioPharma Group Competitors Erasca Competitors Kamada Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COYA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy COYA Stock Free COYA Stock Alerts